CN.[C:3]([O-:6])([O-])=O.[K+].[K+].ClC(OC1C=C[C:16]([N+:19]([O-])=O)=CC=1)=O.[OH:22][C:23]([CH3:53])([CH3:52])[CH2:24][C@@:25]1([C:46]2[CH:51]=[CH:50][CH:49]=[CH:48][CH:47]=2)[O:30][C:29](=[O:31])[N:28]([C@H:32]([C:34]2[CH:39]=[CH:38][C:37]([CH:40]3[CH2:45][CH2:44][NH:43][CH2:42][CH2:41]3)=[CH:36][CH:35]=2)[CH3:33])[CH2:27][CH2:26]1.N>C(#N)C.CCN(CC)CC>[CH3:16][NH:19][C:3]([N:43]1[CH2:44][CH2:45][CH:40]([C:37]2[CH:38]=[CH:39][C:34]([C@@H:32]([N:28]3[CH2:27][CH2:26][C@:25]([CH2:24][C:23]([OH:22])([CH3:52])[CH3:53])([C:46]4[CH:51]=[CH:50][CH:49]=[CH:48][CH:47]=4)[O:30][C:29]3=[O:31])[CH3:33])=[CH:35][CH:36]=2)[CH2:41][CH2:42]1)=[O:6]MeNH2*HCl (27 mg) and K2CO3 (93 mg) were added to a solution of 4-nitrophenyl chloroformate (66 mg) in acetonitrile (2 mL) at room temperature. The resulting mixture was stirred at room temperature for 4 h, before (S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-3-[(S)-1-(4-piperidin-4-yl-phenyl)-ethyl]-[1,3]oxazinan-2-one (110 mg) and NEt3 (53 μL) were added. The mixture was further stirred at room temperature overnight. Then, diluted aqueous ammonia solution was added and the resulting mixture was filtered. The filtrate was concentrated under reduced pressure and the residue was purified by HPLC on reversed phase (MeOH/H2O/NH3) to afford the title compound.